|Bid||4.800 x 0|
|Ask||4.900 x 0|
|Day's Range||4.700 - 4.950|
|52 Week Range||4.200 - 7.460|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.50|
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
HONG KONG, July 5, 2018 /PRNewswire/ -- Sisram Medical Ltd ("Sisram" or "the Company") (Hong Kong: 1696) an investment holding company specializing in medical technology for healthcare, has laid out its vision to become a global MedTech leader, leveraging its solid funding channels, strong R&D capabilities and comprehensive portfolio of products. Sisram has solid financial backing as a member of the Fosun family of companies, a leading investment group with China roots that is gaining a global foothold. Sisram became a publicly-traded company in September 2017, as the first Israeli company to be listed on the Hong Kong Stock Exchange Main Board, under stock code 1696.HK.
"FDA clearance of our innovative Trio applicator once again solidifies Alma's position as the technology and market leader in the global aesthetic market. Soprano is the most recognized brand in the world and we once again have changed the paradigm in aesthetic medicine.